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Abstract
The Italian nephrology has a long tradition and experience in the field of dietetic-nutritional therapy (DNT), which is an 
important component in the conservative management of the patient suffering from a chronic kidney disease, which precedes 
and integrates the pharmacological therapies. The objectives of DNT include the maintenance of an optimal nutritional sta-
tus, the prevention and/or correction of signs, symptoms and complications of chronic renal failure and, possibly, the delay 
in starting of dialysis. The DNT includes modulation of protein intake, adequacy of caloric intake, control of sodium and 
potassium intake, and reduction of phosphorus intake. For all dietary-nutritional therapies, and in particular those aimed at 
the patient with chronic renal failure, the problem of patient adherence to the dietetic-nutritional scheme is a key element for 
the success and safety of the DNT and it can be favored by an interdisciplinary and multi-professional approach of informa-
tion, education, dietary prescription and follow-up. This consensus document, which defines twenty essential points of the 
nutritional approach to patients with advanced chronic renal failure, has been written, discussed and shared by the Italian 
nephrologists together with representatives of dietitians (ANDID) and patients (ANED).
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Introduction
Dietetic-nutritional therapy (DNT) is an important compo-
nent of conservative treatment of patients suffering from 
chronic kidney disease (CKD) which must anticipate and 
be integrated with pharmacological therapies. Objectives 
of DNT are to maintain an optimal nutritional state, pre-
vent and/or correct the signs, symptoms, and complica-
tions related to chronic renal insufficiency, and delay the 
start of dialysis. Furthermore, DNT enables a reduction 
in the drug load (and related side-effects and interactions) 
and can allow for safe and effective use of lower doses of 
dialysis, even when the glomerular filtration rate (GFR) 
continues to diminish. Conservative treatment meth-
ods and incremental dialysis can improve quality of life 
and reduce health care costs. Recently, it has also been 
reported that proper nutrition and lifestyle, such as the 
Dietary Approaches to Stop Hypertension (DASH) diet 
and our own “Mediterranean Diet”, are able to reduce the 
incidence of CKD as well as cardiovascular risk.
Italian nephrologists have a long tradition of and experi-
ence with DNT, founded on, but not limited to, reduction 
of protein intake. In fact, the concept of DNT also includes 
an adequate calorie intake, control of sodium and potas-
sium intakes, and reduction of phosphate intake. Besides 
the quantitative aspects, dietary support also calls for 
modification in the quality of food, in favor of foods of 
plant origin which induce favorable effects on phosphate 
metabolism and acid-base balance with a better control of 
arterial pressure and renal hemodynamics.
For all nutritional therapies, especially those for 
patients with CKD, the patient’s adherence to the dietary 
plan of the DNT is a fundamental element for its suc-
cess and safety. Implementation of an interdisciplinary 
and multi-professional approach to information, educa-
tion, dietary prescription, and follow-up represents a key 
element for better diffusion and success of DNT in the 
nephrological field.
This consensus paper is an example of the difficulty of 
demonstrating what is obvious in the clinical practice and the 
great need for further study in order to improve our under-
standing and knowledge. The Italian Society of Nephrology 
(SIN), through the Working Group on Conservative Thera-
pies of Chronic Kidney Disease, sought to define several 
aspects of the nutritional approach in patients with advanced 
chronic renal insufficiency. A consensus statement consist-
ing of 20 essential points was composed, discussed, and 
shared with dietitians and patients by the National (Italian) 
Association of Dieticians (ANDID) and the National (Ital-
ian) Association of Hemodialysis, Dialysis, and Transplant 
(ANED). This is the first document jointly shared by the 
nephrological scientific community, dieticians, and patients 
concerning essential aspects of the nutritional approach dur-
ing the advanced stages of CKD.
In patients with CKD 4–5, a diet 
with non‑monitored intake of calories, 
protein, sodium, and phosphates hastens 
and exacerbates clinical and metabolic 
alterations related to advanced CKD
As CKD progresses, especially in its most advanced stages, 
various kidney functions tend to become progressively more 
inefficient. In fact, a progressive incapacity to eliminate 
elevated amounts of sodium, water, potassium, phosphorus, 
and hydrogen ions [1] with a tendency towards retention is 
observed. Uncontrolled intake of nutrients and proteins favors 
the onset of metabolic and clinical alterations of the uremic 
status. More specifically, an excess of sodium and water is 
responsible for the onset of arterial hypertension, edema and 
heart failure as well as an increase in oxidative stress [2]. A 
positive balance of phosphorus causes secondary hyperpar-
athyroidism and calcification of the arteries and heart valves, 
with an increase in cardiovascular mortality [3]. Reduced 
capacity to eliminate the fixed acid load, derived from protein 
catabolism, leads to an accumulation of acids with consequent 
metabolic acidosis [4]. Metabolic acidosis stimulates protein 
and muscular catabolism, bone demineralisation, insulin 
resistance, hyperkalemia, etc. [5]. Elimination of nitrogenous 
waste products from catabolism of proteins and amino acids 
also diminishes, resulting in its retention together with that of 
“uremic toxins”, including urea, indole compounds, cresols 
and guanidines [6]. Accumulation of these substances con-
tributes to the onset of anorexia, nausea, and vomiting, with a 
subsequent reduction in intake of energy, proteins, and other 
nutrients [7]. Together, these factors lead to a progressive 
reduction of protein and energy body stores, leading to protein-
energy wasting (PEW) and cachexia, which result in higher 
rates of hospitalization and mortality [8]. They also contribute 
to protein-energy depletion, progressive reduction of physical 
activity and onset of a micro-inflammatory state, more fre-
quent in the advanced stages [9, 10].
In patients with CKD 4–5, a diet 
with non‑monitored intake of energy, 
protein, sodium and phosphate can reduce 
the effectiveness of drug therapy or require 
an increase of dose
Excessive energy intake can contribute to obesity and dys-
lipidemia and exacerbates insulin resistance; it limits the 
effectiveness of antidiabetic and lipid-lowering treatments 
and requires a dosage increase. An elevated sodium intake 
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reduces the effectiveness of antihypertensive and antipro-
teinuric therapies, especially renin–angiotensin–aldoster-
one system (RAAS) inhibitors, with an increased risk of 
CKD progression and medications use, specifically diuret-
ics [11–14].
Elevated consumption of phosphorus inhibits the effec-
tiveness of intestinal phosphate binders and/or requires 
a dosage increase. This contributes to poor control of 
secondary hyperparathyroidism, reducing the therapeutic 
safety of use of active vitamin D preparations. A poor con-
trol of phosphatemia and parathormone (PTH) is associ-
ated with a reduced therapeutic response to erythropoie-
sis-stimulating agents (ESA) and angiotensin-converting 
enzyme (ACE)-inhibitors [15–17].
A high intake of fixed acids, associated with animal 
protein consumption, makes it difficult to prevent meta-
bolic acidosis and requires the use of larger amounts of 
sodium bicarbonate for its correction [18, 19].
Lack of metabolic compensation, 
with the appearance of uremic signs 
and symptoms, is an indication to begin 
dialysis treatment in the same way as, 
and independently of, the level of residual 
renal function
Dialysis is also initiated at relatively high values of GFR in 
the presence of uremic symptoms or because of the belief 
that dialysis provides clinical benefits, better quality of 
life, and less morbidity and mortality [20]. The relation-
ship between the GFR level at the start of dialysis and 
clinical benefits, however, is controversial. The IDEAL 
randomized trial evaluated survival rates associated with 
an early (10–14 ml/min) or late (5–7 ml/min) start and did 
not demonstrate any advantages or disadvantages associ-
ated with the GFR level at the start of dialysis. Initiating 
dialysis at a lower GFR level does not carry greater risk 
to the patient [21]. Dialysis has a major impact on the 
patient’s functional state, especially in very old patients. In 
fact, after just 1 year, only one out of eight older patients 
maintained his functional capacity [22]. Dialysis, while 
improving uremia as well as many other symptoms, is 
not able to assure an acceptable quality of life in many 
patients.
Optimization of the conservative treatment for CKD is 
a rational alternative to early initiation of dialysis. Dialy-
sis should only be started if the uremic symptoms are no 
longer manageable, independently of the level of renal func-
tion [23]. In fact, guidelines indicate clinical cases with cer-
tain characteristics (uremic signs and symptoms and pos-
sible comorbidities) within a wide range of GFR (6–12 ml/
min) who require the start of replacement therapy. Clinical 
features  of untreated uremia (anorexia, hyperazotemia, 
hyperphosphatemia, metabolic acidosis, hydrosaline reten-
tion, malnutrition, etc.) can be controlled with DNT [24].
DNT can postpone, therefore, the start of dialysis even 
with a reduced GFR, thanks to a better control of the ure-
mic signs and symptoms. When correctly carried out with 
an adequate energy intake, it does not have negative effects 
upon the nutritional state and survival rate, both during the 
CKD phase and after the start of dialysis [25, 26]. The good 
metabolic control attained with nutritional treatment, ena-
bles postponement of the start of renal replacement therapy 
to a more advanced stage of the illness with no risk to the 
patient [27, 28].
Untreated chronic renal insufficiency 
leads to undernourishment due to loss 
of appetite, nausea, and anorexia
The natural progression of chronic renal insufficiency leads 
the patient to reduce intake of calories and protein with the 
progressive reduction of residual renal function [29, 30]. 
Alterations caused by renal insufficiency compromise appe-
tite and nutritional status, leading to cachexia and malnutri-
tion [31]. Loss of appetite, anorexia, nausea, or vomiting 
can be caused by uremic toxicity and by decompensated 
metabolic acidosis, both indicators for the start of dialysis. 
In the past, anorexia associated with CKD was attributed 
to the retention of “medium sized molecules” [22, 32, 33]. 
More recently, experimental models of chronic uremia sug-
gest that alterations to the complex neuroendocrine pathways 
operating mainly at the hypothalamic level, could be the 
basis for anorexia.
In fact, substances which accumulate over the course of 
advanced CKD, such as hormones (insulin, leptin, PYY3-36 
produced by the colon, ghrelin) and uremic toxins (cresols, 
indoles, and phenols) could be responsible for the ano-
rexia through neuroendocrine mechanisms [34] involving 
the melanocortin 4 receptor (MC4-R). Increased stimula-
tion of this receptor, suppressing activity of AMP-activated 
protein kinase (AMPK), determines a reduction in food 
consumption.
Other conditions which cause anorexia include delayed 
gastric emptying (as in diabetic gastroparesis), changes in 
taste, uremic halitosis, uremic gastritis, and the high num-
ber of tablets consumed by patients. Chronic inflammation, 
comorbidity, and depression, as well as difficult socio-eco-
nomic situations, can also contribute to malnutrition.
An adequate dietetic-nutritional intervention, with indi-
cation of the correct quantity and quality of protein intake 
coupled with an adequate energy intake and the possible 
addition of sodium bicarbonate supplements (improving 
metabolic acidosis and reducing uremic intoxication), is a 
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therapeutic tool able to reduce anorexia and protein-energy 
depletion in patients with advanced chronic renal insuffi-
ciency [35].
Considering the physiopathology 
of advanced chronic renal insufficiency, 
an adequate dietetic‑nutritional therapy 
provides: reduction of protein intake, 
reduction of phosphorus intake, reduction/
monitoring of sodium intake, monitoring 
of potassium intake, and limitation 
of the fixed acid load
DNT in advanced CKD must be based on limitations of 
protein intake, especially of animal origin, phosphorus, and 
sodium, control of potassium, and satisfaction of energy 
requirement. Such an approach has a precise rationale in 
human physiology: if renal function diminishes, conse-
quently the filtered load must be reduced in order to provide 
residual nephrons with adequate control of the excretion of 
uremic toxins and fixed acids [24]. Appropriate management 
of DNT for CKD in advanced stages requires a reduction in 
protein intake to below 0.8 g/kg/die, which corresponds to 
the recommended intake for the healthy general population 
[36]. There is no scientific rationale for a high-protein diet 
even in cases of elevated proteinuria [24]. Rather, evidence 
exists which indicates that a reduction in food proteins could 
have antiproteinuric effects [17, 37].
Control of phosphorus intake should begin during the initial 
stages of CKD. In fact, under normal physiological conditions, 
a healthy kidney is able to regulate urinary secretions of phos-
phates with food intake, but the progressive loss of glomerular 
filtrate, due to CKD progression, rationalizes a reduction of 
phosphorus intake to below 700 mg/die, the recommended 
level for the general adult population [36]. Surely, it is useful 
to educate patients to avoid consuming “hidden” phosphates 
through additives found in preserved foods or soft drinks [38, 
39]. Choosing foods with a lower phosphorus content and 
using foods of plant origin is useful in limiting the net phos-
phorus load [40]. Finally, food preparation recommendations 
are also important [41]; it has been well documented that boil-
ing food results in demineralization.
Regulating sodium intake is essential for a population in 
which hypertension is almost always present. Limiting sodium 
consumption can improve the protective effects of RAAS 
inhibition and boost antiproteinuric action [42]. Patients with 
hypertension and CKD should immediately limit sodium chlo-
ride food intake to 5–6 g/die (corresponding to a urine sodium 
excretion of 90–100 mmol/die over 24 h) [43, 44]. A low salt 
diet should be avoided under all conditions of sodium-dis-
persing nephropathy to avoid sodium depletion, hypotension, 
and a worsening in renal function. Furthermore, the combined 
reduction of sodium chloride and phosphorus food intake can 
have an antiproteinuric synergistic effect in patients begin 
treated with ACE-inhibitors or sartans [17].
In advanced stages (CKD 4–5) potassium intake should 
be modulated based on serum levels and must be reduced if 
hyperkalemia is > 5.5 mmol/l. In such cases, the possibility 
of withdrawal or reduction of drug regimens which cause 
hyperpotassemia (e.g. ACE inhibitors, sartans, anti-aldoster-
ones) should be considered—after correcting the metabolic 
acidosis—or use of potassium-chelating resins.
A reduced acid load (mainly derivatives of proteins from 
animal-based food sources) is essential in order to reduce 
accumulation and therefore to prevent or correct metabolic 
acidosis [19]. A diet rich in vegetables is the most natu-
ral way to provide stability without resorting to drugs [18]. 
Reduction in the net acid load obtained with a vegetarian 
diet resulted in a 50% reduction in bicarbonate prescrip-
tions [19] and improvement in insulin resistance in diabetics 
[45]. Another important fact is that correction of metabolic 
acidosis (obtained with administration of sodium bicarbo-
nate or with fruits and vegetables) can reduce the loss of 
GFR in subjects with CKD [18]. For this reason, oral bicar-
bonate integration and consuming fruits and vegetables is 
important, while at the same time paying close attention to 
potassium serum levels. Risk of hyperpotassemia is mostly 
associated with taking anti-aldosterones and/or ACE inhibi-
tors and sartans.
To ensure the effectiveness 
of dietetic‑nutritional therapy in chronic 
renal insufficiency, compliance 
with the following conditions must be 
verified: satisfaction of the caloric needs, 
adequate intake of essential amino acids, 
correction of metabolic acidosis, good 
glyco‑metabolic control
Equilibrium of the nitrogen balance is an essential element 
in maintaining a good nutritional status and body compo-
sition. In a stable renal patient, regardless of acute condi-
tions such as fever, sepsis, burns, surgical interventions, 
or steroid therapy, even with a reduced protein intake, the 
nitrogen balance is maintained thanks to a metabolic adap-
tation mechanism, consisting in the organism’s capacity to 
reduce protein catabolism [46–49]. This adaptation to the 
low-protein diet is hindered by conditions which increase the 
nitrogen demand, such as those analyzed below.
An energy  intake lower than   the organism’s needs 
results in the catabolism of protein for energy production: 
the greater the energy deficit, the greater the amount of 
protein used. An elevated energy  intake spares protein and 
allows for a safe reduction in its intake [50]. An inadequate 
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exogenous supply of essential amino acids increases endog-
enous nitrogen catabolism. Although reduced in quantity, 
protein intake must guarantee the needs of essential amino 
acids in the form of natural foods or pharmacological 
supplementation.
Metabolic acidosis accelerates protein and muscle amino 
acid catabolism, stimulating the ubiquitin–proteasome path-
way, which prevents adaptation to the hypoproteic diet. 
Correction of metabolic acidosis is therefore an essential 
prerequisite for nutritional safety of a normo/low protein 
regime [51–53].
Insulin is an anabolic hormone that stimulates the uptake 
of amino acids, increases synthesis and reduces protein 
catabolism: as a result, protein intake requirements increase 
in order to maintain the nitrogenous balance in the presence 
of insulin resistance or poor glycometabolic control in dia-
betic patients [54].
Protein‑free products, made 
up of carbohydrates, contain almost 
no protein, phosphorus, sodium, 
and potassium. They raise caloric intake 
while leaving more space for foods rich 
in high biological value proteins which 
guarantee essential amino acid intake. 
Better therapeutic efficacy is thus obtained 
with a lower risk of nutritional inadequacy
Low protein foods are fundamental to safeguard the cor-
rect elaboration and implementation of a low protein diet in 
patients with chronic renal failure. The use of protein-free 
products allows for an adequate energy intake by excluding/
reducing cereals and derivatives that contain low biologi-
cal value proteins while maintaining consumption of high 
biological value proteins from animal sources. Low protein 
foods are therefore a source of “clean” energy, free from 
nitrogenous waste products and with negligible potassium, 
sodium and phosphorus content. The main obstacles to the 
widespread use of these products include lack of palatabil-
ity and consistency [55, 56], high cost and interregional 
inhomogeneity of delivery methods. Recently, the Italian 
Ministry of Health modified the national standards of care 
to include CKD on the list of chronic diseases exempt from 
copayments. Therefore, a standardization of supply methods 
throughout Italian national territory is expected [57].
The organoleptic differences between low protein foods 
and their common counterparts mainly stem from the 
absence of gluten, a protein that, despite its low biological 
value, has extraordinary technological properties which are 
the basis of pasta production and cooking processes as well 
as bread making processes [58, 59]. The absence of gluten 
limits the consistency, aroma, fragrance and appearance of 
these products. In recent years, however, the food indus-
try has developed alternative production methods, imple-
menting new production technologies and adding substitute 
ingredients such as fibers, with good results [55, 60, 61].
Essential amino acid and ketoacid 
mixture is an useful supplementation 
in CKD patients; it is mandatory on a very 
low‑protein diet
Among dietary regimens proposed to patients with CKD 
4–5, an important role is played by nutritional therapies with 
a reduced protein intake (0.3–0.6 g of protein/kg of body 
weight) and integrated with use of essential amino acids 
(EAA) and ketoacids (KA) mixtures [24, 41]. These nutri-
tional treatments are to be used in motivated patients, who 
have good compliance and do not present severe comorbidi-
ties [26, 62]. By convention, the standard low protein diet 
is based on a contribution of 0.6 g of protein/kg of body 
weight; a very low protein diet (VLPD) is characterized by 
a contribution of less than 0.3 g of plant-based protein/kg 
of body weight [63]. A very low protein and vegetarian diet 
supplies an inadequate amount  of amino acids and so the 
supplementation with KA and EAA is mandatory  [64, 65]. 
The use of these mixtures can also be useful in all cases of 
insufficient spontaneous intake of essential amino acids. In 
the supplemented very low protein diet (sVLPD), one KA 
and EAA tablet is prescribed for every 5 kg of ideal body 
weight. One tablet of KA and EAA contains 500 mg of mix-
ture and provides an intake of 45 mg of calcium salts [66].
Finally, KA and EAA mixtures have a pharmacological 
effect as they contain a significant amount of keto-leucine, 
which has an inhibitory action on protein degradation, while 
leucine is able to promote protein synthesis at the muscle 
level [67].
Therefore, the amino and keto-acid tablets used in nutri-
tional therapies, with low or very low protein intake, satisfy 
EAA needs, allowing for maximum limitation of nitrogen, 
phosphorus and fixed acids load [68, 69].
DNT in CKD 4–5 must be managed according 
to the stages and criteria of any other drug 
therapy: indications, contraindications, 
side effects, changes in dosage, verification 
of results, follow‑up
Indications for DNT include the existence of metabolic 
and hydroelectrolytic alterations or metabolic acidosis, 
protein-energy depletion or obesity, signs and symptoms 
of uremic intoxication, and the desire or necessity to delay 
the start of replacement therapy (dialysis or transplant) 
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[24, 28, 70]. Contraindications include the patient’s refusal 
or inability to follow dietary rules due to socio-economic 
or psychological distress, a chewing disorder, lack of moti-
vation, deterioration in the quality of life, etc. Side effects 
which may limit the duration of and adherence to the nutri-
tional treatment include weight loss due to reduced energy 
intake, caused by poor palatability and loss of appetite, 
dietetic monotony or difficulty in implementation, depres-
sion, and a relationship problems [56, 71]. If these issues 
are not resolved, they can and should lead to a revision 
and/or suspension of DNT.
Changes in dosage: changes in intake of protein, calo-
ries, or other nutrients such as phosphorus, sodium and 
potassium must be adjusted according to the clinical needs 
of each patient and should not be determined a priori by 
the level of RRF [72, 73]. Verification of results: this is 
done using indicators such as urea, phosphorus, PTH, 
hemoglobin, bicarbonate, albumin, body weight, blood 
pressure, need for dialysis, quality of life, etc. [74]. Fol-
low-up: scheduling of clinical, biochemical and nutritional 
check-ups, based on the level of residual renal function 
(RRF), type of DNT and clinical profile. Interactive edu-
cational programs should be conducted engaging various 
professional figures involved in clinical management of 
CKD, in order to improve knowledge, self-management, 
and results of conservative therapy in patients with chronic 
renal failure. Direct patient involvement in diagnostic and 
therapeutic decision-making processes is also crucial  [75, 
76].
Regular evaluation of the nutritional 
and functional status of patients 
with CKD 4–5 at the start of treatment 
and during follow up is essential for diet 
management
In the advanced stages of CKD,  PEW is a quite common 
finding and it represents a negative prognostic factor. It is 
important to predict, diagnose, and characterize PEW and 
monitor the response to nutritional therapy. For assessment 
of nutritional status, several parameters that fall into four 
broad categories, must be used: (1) body mass; (2) mus-
cle mass; (3) biochemical data; and (4) dietary intakes. 
According to a recent report [8], PEW can be diagnosed if 
3 signs/symptoms from the various categories are detected 
3 times over 2–4 consecutive weeks.
Body mass: body weight and its variations and body mass 
index (BMI) fall into this category. Weight is the simplest 
and most effective indicator of an adequate calorie intake 
and should be measured by the patient at home each day 
and at each visit. Both weight and BMI are influenced by 
hydration status and do not provide information about body 
composition. Muscle mass and fat mass: these can be esti-
mated by measuring body circumferences and skinfold thick-
ness. Limits of body fat calipers include the shape of the tool 
and the presence of significant or anasarcatic edemas [77]. 
Bio-impedance analysis can be used to assess body composi-
tion: it is an easy and repeatable clinical method, but it esti-
mates body composition based on mathematical algorithms 
which limits its precision and reliability [78]. Biochemical 
data: this includes monitoring of albumin, prealbumin, cho-
lesterol and transferrin. Conditions such as inflammation, 
level of renal function, or the “iron asset” limit, however, 
sensibility and specificity. Dietary intakes: these are meas-
ured through diet history, 24-h recall and food diaries [79]. 
Measurement of urea, sodium, and phosphorus from 24-h 
urine collection is useful for the objective evaluation of diet 
intakes [80]. Additional methods for assessing nutritional 
status include the Subjective Global Assessment (SGA) [81] 
and the Malnutrition Inflammation Score (MIS) [82].
Recently, functional and performance evaluations have 
also been recommended. Proposed tests include the Barthel 
Index, the Karnowsky Scale, the handgrip test, the Sit-To-
Stand Test, the 6-min Walking Test, the Rapid Assessment 
of Physical Activity (RAPA), pedometers, etc. [83]. Regular 
assessment of a patient’s nutritional and functional status 
allows for prompt intervention and changes to the prescribed 
diet to delay the start of dialysis. A renal dietitian should 
work with the patient’s nephrologist in order to actualize the 
safest and most effective nutritional interventions in patients 
with CKD [84].
Appropriate low protein nutritional therapy 
does not cause malnutrition in the short or 
long term
In    stable CKD  subjects, the minimum amount of die-
tary protein needed to maintain a nitrogen neutral balance 
is about 0.55 g/kg body weight [50]. Protein metabolism is 
closely linked with energy intake and the nitrogen demand 
inversely correlates with the energy  supply. Most patients 
with advanced CKD can maintain a neutral or positive nitro-
gen balance with 0.55 g/kg/day of protein only if they have a 
calorie intake of above 30 kcal/kg/day [50]. With a hypopro-
teic diet, if the patient does not meet daily caloric needs, the 
nitrogen balance becomes negative with protein degradation 
and loss of lean body mass.
Most patients with CKD who are prescribed a low-
protein  diet have a higher protein intake than prescribed, 
while energy  intake is very often reduced below the safety 
threshold [85, 86]. Inability to maintain a sufficient caloric 
intake is due to factors largely related to uremic toxicity 
(e.g. anorexia, nausea, asthenia, depression, abnormalities 
of taste and smell).
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Strict adherence to the calorie prescription (35 kcal/
kg/day in subjects aged < 60 years and 30 kcal/kg/day in 
subjects > 60 years) is essential to maintain neutral or posi-
tive nitrogen balance during a low-protein  diet; prescription 
of a personalized nutritional therapy, with counseling and 
close nutritional monitoring by expert dieticians, allows for 
prompt identification of anomalies and food errors and thus 
reduces risk of malnutrition [24].
In a randomized study involving more than 400 patients 
with CKD stage 3–5 who were monitored for more than 30 
months, only 3 subjects developed malnutrition [87], even 
with very low protein diets, both during the pre-dialysis 
phase and after beginning dialysis [88, 89]. Furthermore, a 
very low-protein  diet prolonged up to the start of dialysis 
does not increase the risk of death during the subsequent 
period of dialysis [26]. In contrast, about half of patients 
with advanced CKD left on a free diet spontaneously reduce 
protein and energy intake, and therefore have a high risk of 
malnutrition [30, 86]. Properly prescribed DNT with careful 
clinical monitoring prevents malnutrition and is safe in both 
the short and long term [90].
Proper dietetic‑nutritional therapy 
in advanced CKD may delay the need 
for replacement therapy. For this reason, 
its use is especially indicated for patients 
in the pre‑emptive kidney transplant 
programme
Nutritional status is one of the main determinants, together 
with cardiovascular comorbidity, of the high mortality of 
dialysis patients. It has been proven that results of renal 
transplant are inversely proportional to the length of time on 
dialysis prior to transplant (the so-called “dialysis vintage”) 
and are better in those with preemptive transplant [91–94].
Nutritional status also influences renal transplant results, 
but there is less data and it is less exhaustive [95–97]. In 
this context, there are few published studies that combine 
hypoproteic diets, nutritional treatment, and preemptive 
transplant. The only exception is a 2004 study of 9 dia-
betic patients awaiting kidney and pancreas transplants, 6 
of whom followed a vegan diet supplemented with EAA 
and KA during the bridge period while awaiting combined 
transplant [98]. Despite the absence of objective data, the 
general observations lead to attempts to delay the start of 
dialysis using an integrated nutritional approach in patients 
awaiting renal or combined transplant.
The approach followed by the Italian school consists, 
in general, of a normocaloric diet, reduced in protein and 
phosphorus, associated with acidosis control and controlled 
sodium intake, carried out under strict clinical surveillance. 
Italian experiments, in line with different experiments 
gathered worldwide, demonstrate the potential for a stand-
ard hypoproteic diet, and, in selected cases, a very low 
protein diet, supplemented with EAA and KA, in different 
populations of patients with advanced chronic renal disease. 
This approach does not result in increased mortality after the 
start of dialysis [26, 99].
Two elements especially favor the systematic use of a 
regimen adapted to stabilize renal function while awaiting 
preemptive transplant: the first is the advantage of avoid-
ing dialysis (it must be emphasized that data favorable to 
preemptive transplant were collected from “standard” 
3-times a week dialysis patients); the second consists of ther-
apeutic compliance which is superior in motivated patients 
with a “positive” outlook. In this regard, it can be expected 
that patients during the pretransplant phase will closely fol-
low the diet plan, in line with different experiences such as 
waiting time to maturation of a vascular access or pregnancy 
[62, 100]. It may be appropriate, therefore to offer DNT to 
patients who may benefit from a predialytic transplant. A 
lack of data, however, makes it necessary to invest in studies 
in order to better define the effectiveness of the nutritional 
approach in preemptive transplant.
In selected patients, proper 
dietetic‑nutritional therapy can 
allow an integrated care approach 
with an once‑a‑week  hemodialysis schedule
In the ‘80s and ‘90s, Giovannetti and Locatelli began the 
Integrated Dialysis Dietary Program (IDDP) in patients with 
GFR < 3 ml/min/1.73 m2, consisting of a weekly hemodialy-
sis session integrated with a very low protein diet equal to 
0.3–0.4 g/kg/day (VLPD) supplemented by essential amino 
acids and their ketoanalogues [101, 102]. Even then, the 
perception that DNT was an important therapeutic tool for 
delaying the start of dialysis was established [103–105]. 
Numerous other reports demonstrate that duration and/or 
frequency of dialysis produces pro-inflammatory and pro-
oxidative cytokine stress which leads a reduction in RRF 
[106]. In 1998, Locatelli et al. suspended IDDP due malnu-
trition risk and poor patient compliance, reporting a drop-out 
rate of 66.6% [107]. A similar approach, called the Com-
bined Diet Dialysis Program (CDDP) [108], has treated more 
than 156 patients until today. The CDDP modified some 
aspects of the IDDP: protein intake of 0.6 g/kg/day with 
free diet on dialysis day, glomerular filtrate between 5–8 ml/
min/1.73 m2, well above previous experiments. Estimation  
of dietary compliance was carried out using the Nitrogen 
Appearance Area formula and RRF with, on average, three 
weekly urine collections, using the mean clearance of urea 
and creatinine. In a controlled, non-randomized study, sig-
nificant advantages of CDDP were shown when compared 
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with patients on hemodialysis three times a week, based on 
measurements of β2-microglobulin and phosphatemia and a 
better preservation of residual diuresis [108]. At 24 months, 
the cumulative survival among the 38 patients on CDDP 
and 30 in standard thrice-a-week hemodialysis schedule  
was identical. Subsequently, at 96 months of follow-up, the 
remaining patients showed a higher cumulative survival rate 
in the CDDP (p < 0.05), highlighting a significant saving on 
indirect costs (hospitalizations) and reduction of direct costs 
by 75% [109, 110]. Thus, although the data derives from a 
non-randomized study, the CDDP in selected, cooperative 
patients may be the best “bridge” option to starting an incre-
mental hemodialysis program.
Proper Dietetic Nutritional Therapy can 
allow an integrated incremental peritoneal 
dialysis regime
Use of incremental peritoneal dialysis (IPD) is justified by 
current guidelines that establish minimum purifying targets, 
by adding peritoneal purification and RRF, that must be 
reached in order to start with a reduced dialysis dose [111]. 
IPD has not yet been defined conclusively. The prevailing 
definition is 1–2 daily treatments for continuous ambulatory 
peritoneal dialysis (PD) and a maximum of 4 weekly ses-
sions in automated PD. It must be emphasized that IPD is 
not early dialysis and requires monthly monitoring of RRF 
to promptly adjust dialytic dosage. Despite little evidence in 
publications, IPD is widely used, mostly in Italy [112]. IPD 
has resulted safe for patients and has shown advantages in 
terms of lower hospitalization, incidence of peritonitis and 
rate of decrease in RRF [113], as well as a lower impact on 
patient quality of life.
Indications for DNT are well defined for CKD 5 [43] 
and for standard PD [114]. Experiences of association 
between DNT and incremental hemodialysis are available 
[109]. With regard to IPD, there are no specific indications 
to date. DNT in IPD could reduce possible occurrence of 
uremic symptoms, improve metabolic control, and contrib-
ute to a delay in RRF decline. The main problems could be 
poor tolerance or adherence to DNT or risk of worsening 
nutritional status and it therefore would require periodic 
metabolic and anthropometric checkups [28]. In Brescia, 
an IPD experiment began in 2002. To date, more than 50% 
of patients start with IPD, prevalently with manual meth-
ods. In all cases DNT is initiated or continued with a daily 
intake of 0.6–0.8 g protein/kg body weight, 30–35 kcal/kg 
body weight and 5 g/day of NaCl.
Beyond this experience, controlled studies are neces-
sary in order to confirm that correct DNT, associated with 
close monitoring of nutritional status and RRF, allows for 
optimization of a IPD regime. After all, the importance 
of renal clearance as compared to peritoneal clearance is 
well known.
Advanced Chronic Kidney Disease 
is characterized by a dysbiosis 
of the intestinal microbiota, which 
contributes to uremic intoxication 
and cardiovascular damage. A hypoproteic 
nutritional therapy, associated 
with adequate fiber intake, can counteract 
dysbiosis and reduce the production 
of uremic toxins
In advanced stages of CKD, a state of dysbiosis of the intes-
tinal microbiota occurs, with alteration of intestinal perme-
ability and bacterial composition, imbalance of microbial 
metabolism in the proteolytic sense, and increased produc-
tion of uremic toxins, such as p-cresol and indoxyl sulfate 
[115]. These toxins, normally excreted by the kidney, accu-
mulate in the patient depending on the disease stage and 
contribute to an accelerated progression towards renal death 
and inflammatory and cardiovascular complications [116].
Dysbiosis worsened in cases of dietary restriction of 
plants and fibers in an attempt to control potassium levels 
[117]. Therefore, the ideal DNT for a patient with advanced 
CKD should include protein restriction and an intake of 
20–30 g/day of dietary fiber, directing the food choices 
towards those containing less phosphorus and potassium 
but with the same fiber content [117]. Desirable beneficial 
effects of this DNT in the advanced CKD could include:1
(a) reduction of intestinal dysbiosis (see footnote 1) [118, 
119];
(b) reduction of circulating uremic toxins [118–121];
(c) reduction of serum creatinine and BUN [122–124];
(d) increase in saccharolytic fermentation and short-chain 
fatty acids (SCFA) at the ascending colon level (see 
footnote 1) [119];
(e) increase in intestinal transit [125] and fecal mass with 
increased excretion of nitrogen compounds [122];
(f) reduction of inflammation [126];
(g) potential reduction of intestinal permeability [127];
(h) potential slowing of CKD progression.
1 Demonstrated in healthy subjects/ clinical contexts different from   
CKD.
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In terms of pharmacoeconomics, 
appropriate Dietetic Nutritional 
Therapy enables cost and resource 
savings in the management of patients 
with advanced chronic renal failure
CKD is a social issue (it affects 7–8% of the population) 
[128], which must be identified early and treated appropri-
ately, preventing its progression towards dialysis in order to 
reduce morbidity, mortality, and costs.
Screening of the general population is not considered 
cost-effective [129]. Patients with progressive renal failure 
who start renal replacement therapy within 4 months of their 
first nephrologist’s appointment show an increase in costs 
when compared to early referrals [130]. Dialysis has very 
high costs compared to predialysis [131, 132]. Data from 
CENSIS 2008 [133] show that dialysis patient care costs 
around € 50,000/year (€ 35,000 for peritoneal dialysis), 
including social care.
Data from the Italian Dialysis and Transplant Registry 
reports an incidence of about 160 patients per million popu-
lation (pmp) with an estimate of about 9600 patients who 
enter dialysis each year and with 40,000 patients on dialysis. 
If the expenditure is about € 50,000 per patient/year, we 
can estimate that the total expenditure for dialysis in Italy 
reaches approximately € 2,000,000,000 per year.
Delaying the start of dialysis by just 1-year results in 
considerable savings: many patients, especially the elderly 
who have a high probability of death within the first year of 
dialysis, could reach end-of-life without ever being subjected 
to dialysis, avoiding suffering for patients and their families 
and contributing to the sustainability of the Italian National 
Healthcare System.
Kidney transplant is the therapy of choice for chronic 
renal failure and the most economical treatment in the long 
run. Costs, over a 3-year observation period, amount to 
€ 95,247, € 52,543 of which are related to the transplant 
itself, specifically surgical procedure and transplant center 
stay [134].
For all these reasons, delaying the start of dialysis 
could result in significant economic savings. A Cochrane 
Meta-Analysis showed that the reduction of protein intake 
reduces the risk of initiating dialysis by 31%, with a Num-
bers Needed to Treat (NNT) value of 17. Use of DNT, in a 
cost-effectiveness analysis, has shown considerable savings 
[135] considering the quality-adjusted life-years (QALYs) 
earned in succession. An effective conservative treatment 
able to postpone dialysis reduces costs up to about € 21,180 
per patient in the first year, € 6500 in the second year and € 
682 in the third year of treatment, with significant benefits 
that favor a diet supplemented with ketoanalogues even in 
worst-case scenarios [136].
A VLPD allows for savings of about € 20,000/year in 
resource consumption for erythropoietin (EPO) [137]. Also 
to bear in mind is the fact that the cost of nutritional inter-
vention, which improves quality of care, means a reduction 
in hospitalization costs before start of dialysis and a timely 
preparation of vascular access with a savings of venous 
catheters.
For a more effective and easier clinical 
management of advanced CKD, it 
is necessary to implement organizational 
models integrating various health 
professionals
CKD represents a public health problem due to its high prev-
alence and high impact on the population’s morbidity and 
mortality [138, 139]. It necessitates development of inter-
ventions aimed at early diagnosis, delay of damage progres-
sion, and prevention of complications. A nephrologist must 
coordinate these activities with the aid of other professionals 
(nurses, psychologists, dieticians, etc.). The most effective 
tool for this purpose is the creation of integrated (diagnostic, 
therapy, assistance) care pathways (ICP) in agreement with 
regional Health Departments.
Pathways of this nature have been initiated in some 
regions: the Prevention of Progressive Renal Failure (PIRP) 
project in the Emilia Romagna Region [140] has been active 
since 2004. Specific clinics have been organized in the 
region’s nephrological centers and a collaboration with ter-
ritorial healthcare has been established; the data collected 
represent an important patrimony for analysis of renal 
disease progression and the incidence of ESRD has been 
reduced. The Lombardian Nephrological Network [141] has 
developed programs to involve general practitioners. Similar 
experiments are present in other areas of the country. In 
Piedmont, the Nephrology Network has structured an inter-
vention model with regards to advanced kidney disease, 
implemented by a Council Decree [142]. This project has 
contributed to the creation, at all nephrology centers, of an 
Advanced Renal Disease Clinic (MaReA). The nephrologist 
coordinates a health professional team (nurses, psycholo-
gists, dieticians) and establishes the timing, means of access 
and check-ups, and plans the replacement therapy implemen-
tation process. Data from treated patients is registered in a 
regional database, connected to the Dialysis and Transplant 
Register. After 4 years, many positive aspects have been 
highlighted as well as several issues. Greater attention was 
paid to the various aspects related to initiation of replace-
ment therapy—a more precocious, sometimes pre-emptive, 
entry onto the transplant list has been achieved, as well 
as renewed interest in home treatment (peritoneal dialysis 
and hemodialysis); collaboration with dietetic services has 
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been activated. The latter services have proven problematic 
in some situations, due in part to a simultaneous regional 
health reorganization. One solution will be sought in a closer 
cooperation with the regional network of clinical nutrition.
To better manage CKD progression and rationalize inter-
ventions in all their aspects, it will be necessary to extend 
the scope of action to include earlier stages of renal damage 
and involve those operating in the local community (general 
practitioners, health districts). It is necessary to seize the 
opportunity offered by the National Chronicity Plan [143], 
which Italian regions must adopt, to develop processes and 
pathways which provide nephrologists with the appropri-
ate tools to coordinate clinical activity needed for a  proper 
CKD patient care.
Dietetic nutritional support levels: full/
part‑time dietitian dedicated to nephrology, 
in‑hospital dietitian, informative materials, 
digital supports
The dietitian involved in CKD nutritional treatment partici-
pates, in collaboration with the nephrologist, in the dietetic-
nutritional program through evaluation of the patient’s nutri-
tional status and development of a personalized dietary plan. 
In addition, the dietician interacts with other team mem-
bers (psychologists, physiotherapists, etc.) to identify and 
promote individual factors that may favor adherence to the 
overall therapeutic plan [144]. A dietitian-provided DNT is 
recommended for CKD patients from stage 1 up to stage 5, 
including dialysis and transplant [145]. The dietician, in col-
laboration with the nephrologist, involves the patient and the 
caregiver in all stages of nutritional treatment, from dietary 
history to formulation, construction and implementation of 
the dietary plan. The dietitian’s role is to provide adequate 
information and education, aimed at self-management of the 
diet in accordance with specific shared objectives.
The National (Italian) Dietitians Association (ANDID) 
supports the recommendation from the National Kidney 
Foundation (NKF) that an expert dietitian should be avail-
able for every 150 nephropathic patients [84]. Visit length 
is a factor that affects the quality of DNT [144]. Available 
evidence shows that 60–90 min are needed for the first 
appointment and 45–60 min for subsequent visits [146]. 
The European Guidelines for Nutritional Assistance 
of adult patients with CKD emphasize that a protein 
intake < 0.8 g/kg of ideal body weight (IBW)/day is not 
to be prescribed if a renal dietitian is not available [147].
The hospital dietician, full-time or part-time dedicated 
to nephrology, carries out his/her activity in collaboration 
with the other professionals involved in the assistance, 
adapting the DNT to the different stages of CKD. He/she 
carries out pedagogical-educational and informational 
activities, aimed respectively at health care and the col-
lective catering personnel. The dietician develops dietetic 
tables for the different stages of CKD, making specifica-
tions for purchase of very low protein dietary products and 
menus for patients of any age and background. The hospi-
tal dietician organizes and coordinates the various people 
involved in feeding services in order to ensure compliance 
with low-protein diet protocols. He/she ensures continuity 
of care through development of a personalized diet plan to 
be implemented after discharge.
Ability to correctly combine biological and psycho-
social aspects of dietary history is a central skill of the 
dietician expert in nutritional treatment of CKD. This 
ability allows for development of personalized diet plans 
that meet both the patient’s tastes and needs [148]. In the 
case of elderly patients, paper supports are to be illus-
trated with involvement of family members or caregivers 
in order to guarantee the best possible practical applica-
tion. Exchange lists, informative brochures, and indica-
tions based on traditional eating habits are also elaborated 
with team collaboration and must guarantee patients a 
wide variety of choices, limiting monotony and the feel-
ing of deprivation associated with traditional approaches 
[149]; emphasis must be placed on what can and should be 
consumed rather than on what is “forbidden”. A telephone 
consultancy service/web platform could be a support in the 
situations where a dietician is not available. Establishment 
of this service should include prescription of a therapeutic 
plan by the nephrologist, development of a DNT plan by 
the dietiian, and subsequent validation by the nephrolo-
gist treating the patient. Various attempts have been made 
to produce computer programs that create diet plans, but 
these do not guarantee protocol customization and limit 
the safety and effectiveness.
Adherence to a dietary prescription 
is critical, as with pharmacological 
therapies. Proper information and education 
when implementing a diet program remain 
at the basis of appropriate chronic patient 
management
In the guideline document for CKD, patient dissatisfaction 
about being poorly informed and involved in their own care 
emerges [150]. The decree on chronicity has patient man-
agement at its core. Much remains to be done, therefore, in 
order to involve renal patients in treatment adherence, which 
is essential for improving results and reducing healthcare 
costs [151–153]. The term “compliance” defines the degree 
to which patient awareness coincides with the recommenda-
tions provided by health professionals [80] and it is often used 
as a synonym for “adherence”. In general, patient adherence 
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to dietetic nutritional therapy is about 31%. Patient involve-
ment is a systematic pathway that identifies and characterizes 
possible means of interaction among the patient, family, car-
egiver, and the health workers. Involvement is a function of the 
gradual choice of patients to take an active role in their health 
management. This process is influenced by individual, social, 
environmental and socio-economic factors.
It is very difficult to act upon processes related to the dis-
ease of a single patient. It is easier to act upon the patient 
care team’s processes of awareness, information, management 
and preparation. Patient and patient care team involvement 
must become the rule within clinical practice and be meas-
ured with appropriate validated scales [154], as they are part 
of the national evaluation and accreditation criteria, and Joint 
Commission International (JCI) certification, at the points 
referring to aspects of patient communication and support for 
self-management. Fundamental to the success of any type of 
treatment is management [155, 156] that can only take place if 
there is a correct involvement of the patient, family, caregivers 
and health professionals (empowerment). Training is essential 
for the development of skills [157] and must be assessed and 
measured if a real desire to increase the effectiveness and effi-
ciency of clinical-care interventions is present. Acquisition of 
communication techniques is fundamental and of support for 
better patient and family member information and involve-
ment. Audiovisual systems, applications, and social networks 
favor the engagement process [158]. Videos can be powerful 
tools as sources of narrative medicine, capturing more easily 
the patient attention.
Healthcare professionals involved in patient 
management with CKD 4–5 should promote 
regular physical activity as an integral part 
of dietetic‑nutritional therapy
Physical activity is a key element in chronic disease pre-
vention, as it improves many aspects including blood pres-
sure control, glucose and lipid metabolism, nutritional 
status, and endothelial function [159]. In contrast, the 
literature is consistent in indicating how sedentariness is 
associated with an increased risk of morbidity and mortal-
ity [160–162]. There are now strong data supporting the 
favorable effects of physical activity in patients with CKD 
who are on a low protein  diet [163], including elderly 
patients [164]. In these patients, physical activity can rep-
resent an important anabolic stimulus that favors nutrient 
use and contrasts loss of lean muscle [163]. Despite this 
evidence, physical activity is rarely prescribed to CKD 
patients [165].
One of the nephrologist’s tasks is to overcome the 
obstacles that frequently oppose implementation of 
“rehabilitative” programs [166]. Lack of knowledge and 
awareness of the importance of physical activity in CKD 
demonstrates the need to create multidisciplinary teams 
in order to implement appropriate physical activity pro-
grams for renal patients [167]. Healthcare professionals 
involved in CKD patient management should promote 
regular physical activity as an integral part of DNT, espe-
cially in advanced stages of the disease.
Conclusion
The following 20 consensus statements have been defined 
to underline several relevant aspects of the nutritional 
approach in patients with advanced chronic renal insuf-
ficiency. These statements were prepared, discussed, and 
shared by Italian nephrologists, dietiians, and patients. 
We believe that they may promote a successful and safe 
implementation of nutritional treatment of CKD patients.
 1. In patients with CKD 4–5, a diet with non-monitored 
intake of calories, protein, sodium, and phosphates 
hastens and exacerbates clinical metabolic alterations 
related to advanced CKD.
 2. In patients with CKD 4–5, a diet with non-monitored 
intake of energy, protein, sodium, and phosphate can 
reduce the effectiveness of drug therapy or require an 
increase of dose.  
 3. Lack of metabolic compensation, with the appear-
ance of uremic signs and symptoms, is an indication 
to begin dialysis treatment, in the same way as and 
independently of the level of residual renal function.
 4. Untreated chronic renal insufficiency leads to under-
nourishment due to loss of appetite, nausea, and ano-
rexia.
 5. Considering the pathophysiology of advanced chronic 
renal insufficiency, an adequate dietetic-nutritional 
therapy provides: reduction of protein intake, reduction 
of phosphorus intake, reduction/monitoring of sodium 
intake, monitoring of potassium intake, limitation of 
the fixed acid load.
 6. To ensure the effectiveness of dietetic-nutritional ther-
apy in chronic renal insufficiency, compliance with the 
following conditions must be verified: satisfaction of 
the caloric needs, adequate intake of essential amino 
acids, correction of metabolic acidosis, good glyco-
metabolic control
 7. Protein-free products, made up of carbohydrates, con-
tain almost no protein, phosphorus, sodium, and potas-
sium. They raise caloric intake while leaving more 
space for foods rich in high biological value proteins 
which guarantee essential amino acid intake. Better 
therapeutic efficacy is thus obtained with a lower risk 
of nutritional inadequacy.
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 8. Essential amino acid and keto acid mixture  is an useful 
supplementation in CKD patients; it is mandatory on 
a very low protein diet.
 9. DNT in CKD 4–5 must be managed according to the 
stages and criteria of any other drug therapy: indica-
tions, contraindications, side effects, changes in dos-
age, verification of results, follow-up.
 10. Regular evaluation of the nutritional and functional sta-
tus of patients with CKD 4–5 at the start of treatment 
and during follow up is essential for diet management.
 11. Proper low protein nutritional therapy does not cause 
malnutrition in the short or long term.
 12. Proper dietetic-nutritional therapy in advanced CKD 
may delay the need for replacement therapy. For this 
reason, its use is especially indicated for patients in the 
preemptive kidney transplant programme.
 13. In selected patients, a proper dietetic-nutritional therapy 
can allow an integrated care approach with once-a-week 
hemodialysis schedule.
 14. Appropriate DNT can allow an integrated incremental 
peritoneal dialysis regime.
 15. Advanced CKD is characterized by a dysbiosis of the 
intestinal microbiota, which contributes to uremic 
intoxication and cardiovascular damage. A hypopro-
teic nutritional therapy, associated with adequate fiber 
intake, can counteract dysbiosis and reduce the produc-
tion of uremic toxins.
 16. In terms of pharmacoeconomics, an appropriate Die-
tetic Nutritional Therapy allows for cost and resource 
savings in the management of patients with advanced 
chronic renal failure.
 17. For a more effective and easier clinical management of 
advanced CKD, it is necessary to implement organiza-
tional models integrating various health professionals.
 18. Dietetic nutritional support levels: full/part-time die-
titian dedicated to Nephrology, in-hospital dietitian, 
informative materials, digital supports
 19. Adherence to a dietary prescription is critical, as with 
pharmacological therapies. Proper information and 
education when implementing a diet program remain 
at the basis of appropriate chronic patient management.
 20. Healthcare professionals involved in patient management 
with CKD 4–5 should promote regular physical activity 
as an integral part of the dietetic-nutritional plan.
Acknowledgements All the authors and the Italian Society of Nephrol-
ogy thank Dr. Schär AG/SPA for an unconditional grant.
Compliance with ethical standards 
Conflict of interest On behalf of all authors, the corresponding author 
states that there is no conflict of interest.
Ethical approval This article does not contain any studies with human 
participants or animals performed by any of the authors.
Informed consent For this type of study formal consent is not required.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Moranne O, Froissart M, Rossert J et al (2009) Timing of onset 
of CKD-related metabolic complications. J Am Soc Nephrol 
20:164–171
 2. Bradbury BD, Fissell RB, Albert JM et al (2007) Predictors 
of early mortality among incident US hemodialysis patients in 
the Dialysis Outcomes and Practice Patterns Study (DOPPS). 
Clin J Am Soc Nephrol 2:89–99
 3. Adeney KL, Siscovick DS, Ix JH et al (2009) Association of 
serum phosphate with vascular and valvular calcification in 
moderate CKD. J Am Soc Nephrol 20:381–387
 4. Reaich D, Channon SM, Scrimgeour CM et al (1993) Cor-
rection of acidosis in humans with CRF decreases protein 
degradation and amino acid oxidation. Am J Physiol 265(2 Pt 
1):E230–E235
 5. Einhorn LM, Zhan M, Hsu VD et al (2009) The frequency of 
hyperkalemia and its significance in chronic kidney disease. 
Arch Intern Med 169:1156–1162
 6. Duranton F, Cohen G, De Smet R et al (2012) Normal and 
pathologic concentrations of uremic toxins. J Am Soc Nephrol 
23(7):1258–1270
 7. Zha Y, Qian Q (2017) Protein nutrition and malnutrition in 
CKD and ESRD. Nutrients. https ://doi.org/10.3390/nu903 0208
 8. Fouque D, Kalantar-Zadeh K, Kopple J et al (2008) A proposed 
nomenclature and diagnostic criteria for protein-energy wasting 
in acute and chronic kidney disease. Kidney Int 73(4):391–398
 9. Eustace JA, Astor B, Muntner PM et al (2004) Prevalence of 
acidosis and inflammation and their association with low serum 
albumin in chronic kidney disease. Kidney Int 65:1031–1040
 10. Kittiskulnam P, Chertow GM, Carrero JJ et al (2017) Sarcopenia 
and its individual criteria are associated, in part, with mortality 
among patients on hemodialysis. Kidney Int 92(1):238–247
 11. De Borst MH, Navis G (2016) Sodium intake, RAAS-blockade 
and progressive renal disease. Pharmacol Res 107:344–351
 12. Zoccali C, Mallamaci F (2016) Salt, cardiovascular risk, obser-
vational research and recommendations for clinical practice. 
Nephrol Dial Transplant 31(9):1405–1408
 13. Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ et  al 
(2015) Fibroblast growth factor 23 and the antiproteinuric 
response to dietary sodium restriction during renin-angiotensin-
aldosterone system blockade. Am J Kidney Dis 65(2):259–266
 14. Humalda JK, Navis G (2014) Dietary sodium restriction: a 
neglected therapeutic opportunity in chronic kidney disease. Curr 
Opin Nephrol Hypertens 23(6):533–540
 15. Zoccali C, Ruggenenti P, Perna A et al (2011) Phosphate may 
promote CKD progression and attenuate renoprotective effect of 
ACE inhibition. J Am Soc Nephrol 22(10):1923–1930
 16. Khairallah P, Isakova T, Asplin J et al (2017) Acid Load and 
Phosphorus Homeostasis in CKD. Am J Kidney Dis 70:541–550
469Journal of Nephrology (2018) 31:457–473 
1 3
 17. Di Iorio BR, Bellizzi V, Bellasi A et al (2013) Phosphate attenu-
ates the anti-proteinuric effect of very low-protein diet in CKD 
patients. Nephrol Dial Transplant 28(3):632–640
 18. Goraya N, Simoni J, Jo CH et al (2014) Treatment of metabolic 
acidosis in patients with stage 3 chronic kidney disease with 
fruits and vegetables or oral bicarbonate reduces urine angio-
tensinogen and preserves glomerular filtration rate. Kidney Int 
86(5):1031–1038. https ://doi.org/10.1038/ki.2014.83.
 19. Di Iorio BR, Di Micco L, Marzocco S et al (2017) Very low-
protein diet (VLPD) reduces metabolic acidosis in subjects with 
chronic kidney disease: the “nutritional light signal” of the renal 
acid load. Nutrients 9(1):69
 20. Rosansky S, Glassock RJ, Clark WF (2011) Early Start of Dialy-
sis: A Critical Review. Clin J Am Soc Nephrol 6:1222–1228
 21. Cooper BA, Branley P, Bulfone L et al (2010) A randomized 
controlled trial of early versus late initiation of dialysis. N Engl 
J Med 363(7):609–619
 22. Kurella Tamura M (2016) Recognition for conservative care in 
kidney failure. Am J Kidney Dis 68(5):671–673
 23. Davison SN, Levin A, Moss AH et al (2015) Executive summary 
of the KDIGO Controversies Conference on Supportive Care in 
Chronic Kidney Disease: developing a roadmap to improving 
quality care. Kidney Int 88(3):447–459
 24. Bellizzi V, Cupisti A, Locatelli F et al (2016) Low-protein diets 
for chronic kidney disease patients: the Italian experience. BMC 
Nephrol 17(1):77
 25. Walser M, Hill S (1999) Can renal replacement be deferred 
by a supplemented very low protein diet? J Am Soc Nephrol 
10(1):110–116
 26. Bellizzi V, Chiodini P, Cupisti A et al (2015) Very low-protein 
diet plus ketoacids in chronic kidney disease and risk of death 
during end-stage renal disease: a historical cohort controlled 
study. Nephrol Dial Transplant 30(1):71–77
 27. Bellizzi V, Carrero JJ, Chauveau P et al (2016) Retarding chronic 
kidney disease (CKD) progression: a practical nutritional 
approach for non-dialysis CKD. Nephrology @ Point of Care 
2(1):e56–e67. https ://doi.org/10.5301/pocj.50002 07
 28. Hanafusa N, Lodebo BY, Kopple JD (2017) Current uses of 
dietary therapy for patients with far-advanced CKD. Clin J Am 
Soc Nephrol 12:1190–1195
 29. Kopple JD, Greene T, Chumlea WC et al (2000) Relationship 
between nutritional status and the glomerular filtration rate: 
results from the MDRD Study. Kidney Int 57:1688–1703
 30. Ikizler TA, Greene JH, Wingard RL et al (1995) Spontaneous 
dietary protein intake during progression of chronic renal failure. 
J Am Soc Nephrol 6:1386–1391
 31. Mitch WE (2002) Malnutrition: a frequent misdiagnosis for 
hemodialysis patients. J Clin Invest 110:437–439
 32. Anderstam B, Mamoun AH, Södersten P et al (1996) Middle-
sized molecule fractions isolated from uremic ultrafiltrate and 
normal urine inhibit ingestive behavior in the rat. J Am Soc 
Nephrol 7:2453–2460
 33. Mamoun AH, Södersten P, Anderstam B et al (1999) Evidence of 
splanchnic-brain signalling in inhibition of ingestive behaviour 
by middle molecules. J Am Soc Nephrol 10:309–314
 34. Mitch WE (2005) Cachexia in chronic kidney disease: a link to 
defective central nervous system control of appetite. J Clin Invest 
115:1476–1478
 35. Kovesdy CP, Kopple JD, Kalantar-Zadeh K (2013) Management 
of protein-energy wasting in non-dialysis-dependent chronic 
kidney disease: reconciling low protein intake with nutritional 
therapy. Am J Clin Nutr 97:1163–1177
 36. LARN (2012) Nutrients and energy reference intake for Italian 
Population. 4th Rev. SINU (Italian Society of Human Nutrition)
 37. Aparicio M, Bellizzi V, Chauveau P et  al (2012) Protein-
restricted diets plus keto/amino acids—a valid therapeutic 
approach for chronic kidney disease patients. J Ren Nutr 22(2 
Suppl):S1-21
 38. Chang AR, Miller ER 3rd, Anderson CA et al (2017) Phosphorus 
additives and albuminuria in early stages of CKD: a randomized 
controlled trial. Am J Kidney Dis 69:200–209
 39. Sullivan C, Sayre SS, Leon JB et al (2009) Effect of food addi-
tives on hyperphosphatemia among patients with end-stage renal 
disease: a randomized controlled trial. JAMA 301(6):629–635
 40. D’Alessandro C, Piccoli GB, Cupisti A (2015) The “phosphorus 
pyramid”: a visual tool for dietary phosphate management in 
dialysis and CKD patients. BMC Nephrol 16:9
 41. D’Alessandro C, Piccoli GB, Calella P et al (2016) “Dietaly”: 
practical issues for the nutritional management of CKD patients 
in Italy. BMC Nephrol 17(1):102
 42. Asghari G, Yuzbashian E, Mirmiran P et al (2017) The associa-
tion between dietary approaches to stop hypertension and inci-
dence of chronic kidney disease in adults: the Tehran lipid and 
glucose study. Nephrol Dial Transplant 32(suppl_2):ii224–ii230
 43. Bellizzi V, Bianchi S, Bolasco P et al (2016) A Delphi consensus 
panel on nutritional therapy in chronic kidney disease. J Nephrol 
29(5):593–602
 44. Kuwabara M, Hisatome I, Roncal-Jimenez CA et  al (2017) 
Increased serum sodium and serum osmolarity are independent 
risk factors for developing chronic kidney disease; 5 year cohort 
study. PLoS One 12(1):e0169137
 45. Bellasi A, Di Micco L, Santoro D et al (2016) Correction of 
metabolic acidosis improves insulin resistance in chronic kidney 
disease. BMC Nephrol 17(1):158
 46. Tom K, Young VR, Chapman T et al (1995) Long-term adaptive 
responses to dietary protein restriction in chronic renal failure. 
Am J Physiol Endocrinol Metab 268:E668–E677
 47. Bernhard J, Beaufrère B, Laville M et  al (2001) Adaptive 
response to a low-protein diet in predialysis chronic renal failure 
patients. J Am Soc Nephrol 12:1249–1254
 48. Masud T, Young VR, Chapman T et al (1994) Adaptive responses 
to very low protein diets: the first comparison of ketoacids to 
essential amino acids. Kidney Int 45:1182–1192
 49. Goodship THJ, Mitch WE, Hoerr RA et al (1990) Adaptation to 
low-protein diets in renal failure: leucine turnover and nitrogen 
balance. J Am Soc Nephrol 1:66–75
 50. Kopple JD, Monteon FJ, Shaib JK (1986) Effect of energy intake 
on nitrogen metabolism in non-dialyzed patients with chronic 
renal failure. Kidney Int 29:734–742
 51. Williams B, Hattersley J, Layward E et al (1991) Metabolic 
acidosis and skeletal muscle adaptation to low protein diets in 
chronic uremia. Kidney Int 40:779–786
 52. Franch HA, Mitch WE (1998) Catabolism in uremia: the impact 
of metabolic acidosis. J Am Soc Nephrol 9(12 Suppl):S78–S81
 53. Bailey JL, Mitch WE (1996) Metabolic acidosis as a uremic 
toxin. Semin Nephrol 16(3):160–166
 54. Rigalleau V, Combe C, Blanchetier V et al (1997) Low protein 
diet in uremia: effects on glucose metabolism and energy produc-
tion rate. Kidney Int 51:1222–1227
 55. Fantuzzi AL, Lugli F, Giannini R (2014) The opinion of patients 
with chronic renal disease on low-protein foods. G Tec Nefrol 
Dial 26(4):361–367
 56. D’Alessandro C, Rossi A, Innocenti M et al (2013) Dietary pro-
tein restriction for renal patients: don’t forget protein-free foods. 
J Ren Nutr 23:367–371
 57. (2017) Decreto del Presidente del Consiglio dei Ministri 12 gen-
naio 2017. Definizione e aggiornamento dei livelli essenziali di 
assistenza, di cui all’articolo 1, comma 7, del decreto legislativo 
30 dicembre 1992, n. 502. GU n.65 del 18/3/2017—Suppl. Ordi-
nario n.15
470 Journal of Nephrology (2018) 31:457–473
1 3
 58. Wagner M, Morel MH, Bonicel J et al (2011) Mechanisms of 
heat-mediated aggregation of wheat gluten protein upon pasta 
processing. J Agric Food Chem 59(7):3146–3154
 59. Delcour JA, Joye IJ, Pareyt B et al (2012) Wheat gluten func-
tionality as a quality determinant in cereal-based food products. 
Annu Rev Food Sci Technol 3:469–492
 60. Sabanis D, Lebesi D, Tzia C (2009) Development of fibre-
enriched gluten-free bread: a response surface methodology 
study. Int J Food Sci Nutr 60:174–190
 61. Alvarez-Jubete L, Arendt EK, Gallagher E (2009) Nutritive value 
and chemical composition of pseudocereals as gluten-free ingre-
dients. Int J Food Sci Nutr 60:240–257
 62. Fouque D, Chen J, Chen W et al (2016) Adherence to ketoacids/
essential amino acids-supplemented low protein diets and new 
indications for patients with chronic kidney disease. BMC Neph-
rol 17:63
 63. Goraya N, Wesson DE (2015) Dietary interventions to improve 
outcomes in chronic kidney disease. Curr Opin Nephrol Hyper-
tens 24:505–510
 64. Garneata L, Stancu A, Dragomir D et al (2016) Ketoanalogue-
supplemented vegetarian very low-protein diet and CKD progres-
sion. J Am Soc Nephrol 27:2164–2176
 65. Aparicio M, Bellizzi V, Chauveau P et al (2013) Do ketoana-
logues still have a role in delaying dialysis initiation in CKD 
predialysis patients? Semin Dial 26:714–719
 66. Di Iorio BR, Minutolo R, De Nicola L et al (2003) Supplemented 
very low protein diet ameliorates responsiveness to erythropoi-
etin in chronic renal failure. Kidney Int 64:1822–1828
 67. Mitch WE, Walser M, Sapir DG (1981) Nitrogen sparing 
induced by leucine compared with that induced by its keto ana-
logue, alpha-ketoisocaproato, in fasting obese man. J Clin Invest 
67(2):553–562
 68. Wesson DE, Simoni J (2010) Acid retention during kidney fail-
ure induces endothelin and aldosterone production which lead to 
progressive GFR decline, a situation ameliorated by alkali diet. 
Kidney Int 78:1128–1135
 69. Brunori G, Viola BF, Parrinello G et al (2007) Efficacy and 
safety of a very-low-protein diet when postponing dialysis in the 
elderly: a prospective randomized multicenter controlled study. 
Am J Kidney Dis 49:569–580
 70. Mitch WE, Remuzzi G (2016) Diets for patients with chronic 
kidney disease, should we reconsider? BMC Nephrol 17:80
 71. Piccoli GB, Deagostini MC, Vigotti FN et al (2014) Which low-
protein diet for which CKD patient? An observational, personal-
ized approach. Nutrition 30:992–999
 72. Aparicio M, Bellizzi V, Chauveau P et al (2012) Keto acid ther-
apy in predialysis chronic kidney disease patients: Final consen-
sus. J Ren Nutr 22:S22–S24
 73. Cupisti A, D’Alessandro C, Di Iorio B et al (2016) Nutritional 
support in the tertiary care of patients affected by chronic renal 
insufficiency: report of a step-wise, personalized, pragmatic 
approach. BMC Nephrol 17(1):124
 74. Kovesdy CP, Kalantar-Zadeh K (2016) Back to the future: 
Restricted protein intake for conservative management of CKD, 
triple goals of renoprotection, uremia mitigation, and nutritional 
health. Int Urol Nephrol 48:725–729
 75. Coyne T, Olson M, Bradham K et al (1995) Dietary satisfaction 
correlated with adherence in the Modification of Diet in Renal 
Disease Study. J Am Diet Assoc 95(11):1301–1306
 76. Lopez-Vargas PA, Tong A, Howell M et al (2016) Educational 
interventions for patients With CKD: a systematic review. Am J 
Kidney Dis 68(3):353–370
 77. Pasticci F, Fantuzzi AL, Pegoraro M et al (2012) Nutritional 
management of stage 5 chronic kidney disease. J Ren Care 
38(1):50–58
 78. Pupim LB, Ikizler TA (2004) Assessment and Monitoring of 
Uremic Malnutrition. J Ren Nutr 14:6–19
 79. Fantuzzi AL, Gennari A, Pasticci F et al (2002) Ruolo del dietista 
nella gestione nutrizionale del paziente con malattia renale cron-
ica. Posizione ANDID
 80. Bellizzi V, Bedogni G, Quintaliani G (2008) Compliance with 
low protein diet in patients with chronic kidney disease. G Ital 
Nefrol 25(Suppl 42):S45-9
 81. Steiber AL, Kalantar-Zadeh K, Secker D et al (2004) Subjective 
global assessment in chronic kidney disease: a review. J Ren Nutr 
4:191–200
 82. Kalantar-Zadeh K, Kopple JD, Block G et al (2001) A malnutri-
tion-inflammation score is correlated with morbidity and mor-
tality in maintenance hemodialysis patients. Am J Kidney Dis 
38(6):1251–1263
 83. Cupisti A, D’Alessandro C, Finato V et al (2017) Assessment of 
physical activity, capacity and nutritional status in elderly peri-
toneal dialysis patients. BMC Nephrol 18:180
 84. (2000) Clinical practice guidelines for nutrition in chronic renal 
failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 
35(6)(Suppl 2):S1–S140
 85. Cianciaruso B, Capuano A, D’Amaro E et al (1989) Dietary 
compliance to a low protein and phosphate diet in patients with 
chronic renal failure. Kidney Int 27:S173–S176
 86. Kopple JD, Levey AS, Greene T et al (1997) Effect of dietary 
protein restriction on nutritional status in the Modification of 
Diet in Renal Disease Study. Kidney Int 52:778–791
 87. Cianciaruso B, Pota A, Bellizzi V et  al (2009) Effect of a 
low- versus moderate-protein diet on progression of CKD: 
follow-up of a randomized controlled trial. Am J Kidney Dis 
54(6):1052–1061
 88. Chauveau P, Barthe N, Rigalleau V et al (1999) Outcome of 
nutritional status and body composition of uremic patients on a 
very low protein diet. Am J Kidney Dis 34(3):500–507
 89. Vendrely B, Chauveau P, Barthe N et al (2003) Nutrition in 
hemodialysis patients previously on a supplemented very low 
protein diet. Kidney Int 63(4):1491–1498
 90. Dukkipati R, Noori N, Feroze U et al (2010) Dietary protein 
intake in patients with advanced chronic kidney disease and on 
dialysis. Semin Dial 23(4):365–372
 91. Meier-Kriesche HU, Schold JD, Srinivas TR et  al (2004) 
Kidney transplantation halts cardiovascular disease progres-
sion in patients with end-stage renal disease. Am J Transplant 
4(10):1662–1668
 92. Augustine JJ, Poggio ED, Clemente M et al (2007) Hemodialysis 
vintage, black ethnicity, and pretransplantation antidonor cellu-
lar immunity in kidney transplant recipients. J Am Soc Nephrol 
18(5):1602–1606
 93. Haller MC, Kainz A, Baer H et al (2017) Dialysis vintage and 
outcomes after kidney transplantation: a retrospective cohort 
study. Clin J Am Soc Nephrol 12(1):122–130
 94. Papalois VE, Moss A, Gillingham KJ et al (2000) Pre-emptive 
transplants for patients with renal failure: an argument against 
waiting until dialysis. Transplantation 70(4):625–631
 95. Streja E, Molnar MZ, Kovesdy CP et al (2011) Associations of 
pretransplant weight and muscle mass with mortality in renal 
transplant recipients. Clin J Am Soc Nephrol 6(6):1463–1473
 96. Molnar MZ, Nguyen DV, Chen Y et  al (2017) Predictive 
score for posttransplantation outcomes. Transplantation 
101(6):1353–1364
 97. Piccoli GB, Moio MR, Fois A et al (2017) The diet and hae-
modialysis dyad: three eras, four open questions and four 
paradoxes. a narrative review, towards a personalized. Patient 
Centered Approach Nutr. https ://doi.org/10.3390/nu904 0372
471Journal of Nephrology (2018) 31:457–473 
1 3
 98. Piccoli GB, Motta D, Martina G et al (2004) Low-protein veg-
etarian diet with alpha-chetoanalogues prior to pre-emptive 
pancreas-kidney transplantation. Rev Diabet Stud 1:95–102
 99. Chauveau P, Couzi L, Vendrely B et al (2009) Long-term out-
come on renal replacement therapy in patients who previously 
received a keto acid-supplemented very-low-protein diet. Am 
J Clin Nutr 90(4):969–974
 100. Attini R, Leone F, Parisi S et al (2016) Vegan-vegetarian low-
protein supplemented diets in pregnant CKD patients: fifteen 
years of experience. BMC Nephrol 17(1):132
 101. Locatelli F, Andrulli S, Pontoriero G et al (1994) Supple-
mented low-protein diet and once-weekly hemodialysis. Am 
J Kidney Dis 24(2):192–204
 102. Morelli E, Baldi R, Barsotti G et al (1987) Combined therapy 
for selected chronic uremic patients: infrequent hemodialysis 
and nutritional management. Nephron 47(3):161–166
 103. Levey AS, Adler S, Caggiula AW et al (1996) Effects of dietary 
protein restriction on the progression of advanced renal dis-
ease in the Modification of Diet in Renal Disease Study. Am J 
Kidney Dis 27(5):652–663
 104. Fouque D, Laville M, Boissel JP. Low protein diets for chronic 
kidney disease in non diabetic adults. Cochrane Database Syst 
Rev 2006;(2):CD001892
 105. Zemchenkov A, Konakova IN (2016) Efficacy of the essential 
amino acids and keto-analogues on the CKD progression rate 
in real practice in Russia-city nephrology registry data for out-
patient clinic. BMC Nephrol 17:62
 106. Daugirdas JT, Greene T, Rocco MV et al (2013) Effect of fre-
quent hemodialysis on residual kidney function. Kidney Int 
83(5):949–958
 107. Locatelli F, Andrulli S, Pontoriero G et al (1998) Integrated 
diet and dialysis programme. Nephrol Dial Transplant 13(Suppl 
6):132–138
 108. Caria S, Cupisti A, Bolasco P (2014) The incremental treat-
ment of ESRD: a low-protein diet combined with weekly 
hemodialysis may be beneficial for selected patients. BMC 
Nephrol 15:172
 109. Bolasco P, Cupisti A, Locatelli F et al (2016) Dietary manage-
ment of incremental transition to dialysis therapy: once-weekly 
hemodialysis combined with low-protein diet. J Ren Nutr 
26(6):352–359
 110. Bolasco P (2017) Nutritional hypoproteic approach and phos-
phate control allows the incremental hemodialysis. In: 11th Euro-
pean nutrition and dietetics conference
 111. Lo WK, Bargman JM, Burkart J et al (2006) Guideline on targets 
for solute and fluid removal in adult patients on chronic perito-
neal dialysis. Perit Dial Int 26(5):520–522
 112. Neri L, Viglino G, Marinangeli G et al (2017) Incremental start 
to PD as experienced in Italy: results of census carried out from 
2005 to 2014. J Nephrol 30(4):593–599
 113. Sandrini M, Vizzardi V, Valerio F et al (2016) Incremental 
peritoneal dialysis: a 10 year single-centre experience. J Neph-
rol 29(6):871–879
 114. Tennankore KK, Bargman JM (2013) Nutrition and the kidney: 
recommendations for peritoneal dialysis. Adv Chronic Kidney 
Dis 20(2):190–201
 115. Montemurno E, Cosola C, Dalfino G et al (2014) What would 
you like to eat, Mr CKD microbiota? A mediterranean diet. 
Kidney Blood Press Res 39(2–3):114–123
 116. Vanholder R, Schepers E, Pletinck A et al (2014) The uremic 
toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic 
review. J Am Soc Nephrol 25(9):1897–1907
 117. Cupisti A, D’Alessandro C, Gesualdo L et al (2017) Non-tradi-
tional aspects of renal diets: focus on fiber, alkali and vitamin 
K1 intake. Nutrients. https ://doi.org/10.3390/nu905 0444
 118. Sabatino A, Regolisti G, Cosola C et al (2017) Intestinal micro-
biota in type 2 diabetes and chronic kidney disease. Curr Diab 
Rep 17(3):16
 119. De Angelis M, Montemurno E, Vannini L et al (2015) Effect of 
whole-grain barley on the human fecal microbiota and metabo-
lome. Appl Environ Microbiol 81:7945–7956
 120. Cosola C, De Angelis M, Rocchetti MT et al (2017) Beta-
glucans supplementation associates with reduction in p-cresyl 
sulfate levels and improved endothelial vascular reactivity in 
healthy individuals. PLoS One 12(1):e0169635
 121. Rossi M, Johnson DW, Xu H et al (2015) Dietary protein-fiber 
ratio associates with circulating levels of indoxyl sulfate and 
p-cresyl sulfate in chronic kidney disease patients. Nutr Metab 
Cardiovasc Dis 25(9):860–865
 122. Bliss DZ, Stein TP, Schleifer CR et al (1996) Supplementa-
tion with gum arabic fiber increases fecal nitrogen excretion 
and lowers serum urea nitrogen concentration in chronic renal 
failure patients consuming a low-protein diet. Am J Clin Nutr 
63(3):392–398
 123. Chiavaroli L, Mirrahimi A, Sievenpiper JL et al (2015) Dietary 
fiber effects in chronic kidney disease: a systematic review 
and meta-analysis of controlled feeding trials. Eur J Clin Nutr 
69(7):761–768
 124. Di Iorio BR, Marzocco S, Bellasi A et al (2017) Nutritional 
therapy reduces protein carbamylation through urea lowering 
in chronic kidney disease. Nephrol Dial Transplant. https ://doi.
org/10.1093/ndt/gfx20 3
 125. Salmean YA, Zello GA, Dahl WJ (2013) Foods with added 
fiber improve stool frequency in individuals with chronic kid-
ney disease with no impact on appetite or overall quality of life. 
BMC Res Notes 6:510
 126. Krishnamurthy VM, Wei G, Baird BC et al (2012) High dietary 
fiber intake is associated with decreased inflammation and all-
cause mortality in patients with chronic kidney disease. Kidney 
Int 81(3):300–306
 127. Sabatino A, Regolisti G, Brusasco I et al (2015) Alterations 
of intestinal barrier and microbiota in chronic kidney disease. 
Nephrol Dial Transplant 30:924–933
 128. Documento di indirizzo per la malattia renale cronica. http://
www.salut e.gov.it/porta le/docum entaz ione/p6_2_2_1.jsp?lingu 
a=itali ano&id=2244
 129. Vekemana F, Yameogo ND, Lefebvreb P et al (2010) Health-
care costs associated with nephrology care in pre-dialysis 
chronic kidney disease patients. J Med Econ 13(4):673–680
 130. McLaughlin K, Manns B, Culleton B et al (2001) An economic 
evaluation of early versus late referral of patients with progres-
sive renal insufficiency. Am J Kidney Dis 38:1122–1128
 131. Roggeri DP, Roggeri A, Salomone M (2014) Chronic kidney 
disease: evolution of healthcare costs and resource consump-
tion from predialysis to dialysis in Piedmont Region, Italy. Adv 
Nephrol. https ://doi.org/10.1155/2014/68073 7
 132. Turchetti G, Bellelli S, Amato M et al (2017) The social cost of 
chronic kidney disease in Italy. Eur J Health Econ 18:847–858
 133. Censis (2008) I trattamenti sostituitivi della funzione renale in 
Italia: aspetti clinici, economici e sociali, Roma
 134. Censis, Vaccaro CM, del Trapianto IV (2013) I consumi sanitari 
ed i costi dei trapiantati di rene in Italia. Carocci ed, Roma
 135. Mennini FS, Russo S, Marcellusi A et al (2014) Economic effects 
of treatment of chronic kidney disease with low-protein diet. J 
Ren Nutr 24(5):313–321
 136. Scalone L, Borghetti F, Brunori G et al (2010) Cost-benefit 
analysis of supplemented very low-protein diet versus dialysis 
in elderly CKD5 patients. Nephrol Dial Transplant 25:907–913
 137. Di Iorio BR, Bellizzi V, Minutolo R et al (2004) Supplemented 
very low protein diet in advanced CRF: is it money saving? Kid-
ney Int 65:742
472 Journal of Nephrology (2018) 31:457–473
1 3
 138. Radhakrishnan J, Remuzzi G, Saran R et al (2014) Taming the 
chronic kidney disease epidemic: a global view of surveillance 
efforts. Kidney Int 86(2):246–250
 139. Stenvinkel P (2010) Chronic kidney disease: a public health pri-
ority and harbinger of premature cardiovascular disease. J Intern 
Med 268(5):456–467
 140. REGIONE EMILIA ROMAGNA. http://salut e.regio ne.emili 
a-romag na.it/campa gne/campa gne-infor mativ e-scadu te/insuf 
ficie nza-renal e
 141. REGIONE LOMBARDIA Decreto n, 1074—12.02.2013—
identificativo atto n. 61. http://www.regio ne.lomba rdia.it/wps/
wcm/conne ct/cd311 9a5-db9e-4f7c-a0a3-21ef5 1fa6e ab/Decre 
to+appro vazio ne+docum enti+sotto grupp i.pdf?MOD=AJPER 
ES&CACHE ID=cd311 9a5-db9e-4f7c-a0a3-21ef5 1fa6e ab
 142. REGIONE PIEMONTE BU36 05/09/2013. http://www.regio 
ne.piemo nte.it/gover no/bolle ttino /abbon ati/2013/36/attac h/
dgr_06290 _830_02082 013.pdf
 143. Ministero Salute 2016—PNC Piano Nazionale delle Criticità. 
http://www.trova norme .salut e.gov.it/norme /rende rNorm sanPd 
f?anno=2016&codLe g=56361 &parte =1%20&serie =null
 144. Fantuzzi AL, Gennari AL, Pasticci F et al (2005) Posizione 
ANDID: Ruolo del Dietista nella gesione nutrizionale del 
paziente con malattia renale cronica. ANDID notizie, speciale 
5:23–24
 145. (2012) Academy of Nutrition and Dietetics Chronic Kidney 
Disease (CKD) Evidence-Based Nutrition Practice Guideline: 
Evidence Analysis Library 2012. http://andev idenc elibr ary.com/
topic .cfm?forma t_table s=0&cat=3929
 146. American Dietetic Association (2002) Medical nutrition therapy: 
chronic kidney disease (non-dialysis). Chicago (CD-ROM)
 147. EDTNA/ERCA Dietitians Special Interest Group (2002) Euro-
pean guidelines for nutritional care of adult renal patients
 148. Kopple JD (1994) Nutrition, diet and the kidney. In: Shils ME, 
Olson JA, Shike M (eds) Modern nutrition in health and disease. 
Lea and Febiger, Philadelphia, pp 1102–1134
 149. Fantuzzi AL, Bedogni G (2001) Dieta ipoproteica e insufficienza 
renale cronica. UTET S.p.A. Divisione periodici scientifici, 
Milano, pp 50–53
 150. Documento di indirizzo per la malattia renale cronica e decreto 
cronicita’. https ://renal gate.wordp ress.com/malat tia-renal e-croni 
ca/
 151. Graffigna G, Barello S, Riva G et al (2014) Patient engagement: 
the key to redesign the exchange between the demand and supply 
for healthcare in the era of active ageing. Stud Health Technol 
Inform 203:85–95
 152. Oshima Lee E, Emanuel EJ (2013) Shared decision making to 
improve care and reduce costs. N Engl J Med 368(1):6–8
 153. Goovaerts T, Jadoul M, Goffin E (2005) Influence of a pre-dialy-
sis education programme (PDEP) on the mode of renal replace-
ment therapy. Nephrol Dial Transplant 20:1842–1847
 154. Barello S, Graffigna G, Pitacco G et al (2016) An educational 
intervention to train professional nurses in promoting patient 
engagement: a pilot feasibility study. Front Psychol 7:2020. https 
://doi.org/10.3389/fpsyg .2016.02020 
 155. Laurance J, Henderson S, Howitt PJ et al (2014) Patient Engage-
ment: four case studies that highlight the potential for improved 
health outcomes and reduced costs. Health Aff 33(9):1627–1634
 156. Stewart M (2001) Towards a global definition of patient centred 
care. BMJ 322:444–445
 157. Charles C, Gafni A, Whelan T (2000) How to improve com-
munication between doctors and patients: learning more 
about the decision making context is important. BMJ 
320(7244):1220–1221
 158. Solomon M, Wagner SL, Goes J (2012) Effects of a Web-based 
intervention for adults with chronic conditions on patient acti-
vation: online randomized controlled trial. J Med Internet Res 
14(1):e32
 159. Barcellos FC, Santos IS, Umpierre D et al (2015) Effects of exer-
cise in the whole spectrum of chronic kidney disease: a system-
atic review. Clin Kidney J 8:753–765
 160. Lee IM, Shiroma EJ, Lobelo F et al (2012) Effect of physical 
inactivity on major non-communicable disease worldwide: 
an analysis of burden of disease and life expectancy. Lancet 
380:219–229
 161. O’Hare AM, Tawney K, Bacchetti P et al (2003) Decreased 
survival among sedentary patients undergoing dialysis: results 
from the Dialysis Morbidity and Mortality Study Wave 2. Am J 
Kidney Dis 41:447–454
 162. Sietsema KE, Amato A, Adler SG et al (2004) Exercise capacity 
as a predictor of survival among ambulatory patients with end-
stage renal disease. Kidney Int 65(2):719–724
 163. Painter P, Roshanvaran B (2013) The association of physi-
cal activity and physical function with clinical outcomes in 
adults with chronic kidney disease. Curr Opin Nephrol Hypert 
22:615–623
 164. Heiwe S, Jacobson SH (2011) Exercise training for adults 
with chronic kidney disease. Cochrane Database Syst Rev 
10:CD003236. https ://doi.org/10.1002/14651 858.CD003 236.
pub2
 165. Heiwe S, Tollbäck A, Clyne N (2001) Twelve weeks of exer-
cise training increases muscle function and walking capacity 
in elderly predialysis patients and healthy subjects. Nephron 
88:48–56
 166. Regolisti G, Maggiore U, Sabatino A et al (2018) Interaction 
of healthcare staff’s attitude with barriers to physical activity 
in hemodialysis patients: a quantitative assessment. PLoS One 
13(4):e0196313
 167. Capitanini A, Lange S, D’Alessandro C et al (2014) Dialysis exer-
cise team: the way to sustain exercise programs in hemodialysis 
patients. Kidney Blood Press Res 39:129–133
Affiliations
Adamasco Cupisti1 · Giuliano Brunori2 · Biagio Raffaele Di Iorio3 · Claudia D’Alessandro1,4 · Franca Pasticci4,5 · 
Carmela Cosola6 · Vincenzo Bellizzi7 · Piergiorgio Bolasco8 · Alessandro Capitanini9 · Anna Laura Fantuzzi10 · 
Annalisa Gennari4,11 · Giorgina Barbara Piccoli12,13 · Giuseppe Quintaliani14 · Mario Salomone15 · 
Massimo Sandrini11 · Domenico Santoro16 · Patrizia Babini17 · Enrico Fiaccadori18 · Giovanni Gambaro19 · 
Giacomo Garibotto20 · Mariacristina Gregorini21 · Marcora Mandreoli22 · Roberto Minutolo23 · Giovanni Cancarini11 · 
Giuseppe Conte23 · Francesco Locatelli24 · Loreto Gesualdo6
1 Dipartimento di Medicina Clinica e Sperimentale, Università 
di Pisa, Via Roma 67, 56126 Pisa, Italy
2 SC Multizonale di Nefrologia e Dialisi, APSS, Trento, Italy
3 UOC di Nefrologia, PO “A. Landolfi”, Solofra, AV, Italy
473Journal of Nephrology (2018) 31:457–473 
1 3
4 ANDID Associazione Nazionale Dietisti, Verona, Italy
5 Dipartimento di Medicina, USL Umbria 1, Perugia, Italy
6 Dipartimento dell’Emergenza e dei Trapianti di Organi 
D.E.T.O. - Sezione di Nefrologia, Dialisi e Trapianti, 
Università degli Studi di Bari Aldo Moro, Bari, Italy
7 Divisione di Nefrologia, Dialisi e Trapianto Azienda 
Ospedaliera Universitaria “San Giovanni di Dio e Ruggi 
d’Aragona” Salerno, Salerno, Italy
8 Nefrologia e Dialisi, ASL Cagliari Consultant, Cagliari, Italy
9 SOS Nefrologia Pistoia, ASL Toscana Centro, Florence, Italy
10 Nutrizione e Dietetica Aziendale, AUSL Modena, Modena, 
Italy
11 UO Nefrologia, ASST Spedali Civili e Università di Brescia, 
Brescia, Italy
12 Dipartimento di Scienze Cliniche e Biologiche, Università di 
Torino, Turin, Italy
13 Centre Hospitalier Le Mans, Le Mans, France
14 Nefrologia e Dialisi, Azienda Ospedaliera di Perugia, 
Perugia, Italy
15 Nefrologia e Dialisi, ASL TO5, Chieri, TO, Italy
16 Dipartimento di Medicina Clinica e Sperimentale-UOC di 
Nefrologia e Dialisi, Università di Messina, Messina, Italy
17 ANED Onlus, Milan, Italy
18 Unità di Fisiopatologia Insufficienza Renale, Università di 
Parma, Parma, Italy
19 Dipartimento di Medicina, Università Cattolica del Sacro 
Cuore, Rome, Italy
20 Università degli Studi di Genova, DIMI and IRCCS AOU 
San Martino IST, Genoa, Italy
21 SC Nefrologia e Dialisi Arcispedale S. Maria Nuova Azienda 
USL Reggio Emilia, Reggio Emilia, Italy
22 Nefrologia e Dialisi, Ospedale S. Maria Scaletta, Azienda 
USL Imola, Imola, Italy
23 Divisione di Nefrologia, Università della Campania “Luigi 
Vanvitelli”, Naples, Italy
24 SC Nefrologia e Dialisi, Ospedale Manzoni, ASST, Lecco, 
Italy
